BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Immunotherapeutics Announces Proposed Public Offering

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsFinancing

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary

Related news

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

STTKShattuck Labs2026-06-09 20:18 EST

Shattuck Labs, Inc. Announces Proposed Public Offering

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

HCWBHCW Biologics2026-07-29 13:06 EST

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

HCWBHCW Biologics2026-05-21 13:53 EST

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

VYNEVYNE Therapeutics Inc.2026-07-21 12:00 EST

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobody technology. Nanobodies are compact antibody-derived domains that may provide strong tissue penetration and flexible molecular design. Sonelokimab Sonelokimab is a trivalent Nanobody designed to inhibit IL-17A and IL-17F while...

Recent company news

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-03-28 19:00 EST

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Stock data

Close
18.03 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States